Trial Profile
A retrospective study evaluated effectiveness and safety of Sofosbuvir/Velpatasvir ± Ribavirin for retreatment of patients with Chronic Hepatitis C Virus infection who failed previous therapy with direct antiviral agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases